近日，在深圳市光明区召开的"第五届脑科学前沿与产业大会"上，深圳市眼科医院院长迟玮教授围绕 《从眼到脑，植入式脑机接口视觉重建之路》这一主题作专题报告，并首次公开分享了团队的最新研究 脑机接口产业是中央和地方"十五五"规划建议前瞻布局的未来产业之一，也是深圳市眼科医院成立"眼 －脑实验室"布局发展的重点科研方向。 进展。 迟玮教授领衔的合作研究团队已率先在非人灵长类动物身上成功实现了无线、百通道视觉皮层假体的手 术植入，并开展了各类验证试验。 该植入体是目前全球体积最小的半侵入式脑机接口视觉植入产品，造成的创伤和风险较小。植入体通过 无线传输的方式将控制单元数据能量传输至贴片刺激部分，进而刺激视觉皮层。试验结果显示，电刺激 成功诱发了视觉皮层神经元放电，这标志着此项试验真正实现了全链条的无线视觉刺激过程，为下一阶 段的IIT临床研究奠定了基础。 这一技术的实现为国内首创，首次验证了一种最小侵入、易推广的视觉重建技术的先进性和有效性，体 现了脑机接口技术在视觉重建领域的重大突破。 自2020年起，深圳市眼科医院与试验合作方深圳市中科先见医疗科技有限公司紧密携手，双方借助医工 交叉、产研融合的模式，在视觉重建领域 ...

Core Points - The establishment of the Suzhou Integration Development Center by the Chinese Microcirculation Society aims to enhance the management of chronic diseases and promote innovation in the biomedicine industry in Suzhou [1][2] - The center will focus on technology transfer, professional talent training, and the development of technical standards in the field of chronic disease screening and prevention [1] - The collaboration between the Chinese Microcirculation Society, Suzhou Science and Technology Association, and Southeast University Suzhou Research Institute is aligned with the strategic needs of high-quality development in the biomedicine sector and the "Healthy Suzhou" initiative [1] Group 1 - The center's establishment is expected to gather top expert resources and cutting-edge technological achievements to facilitate breakthroughs in microcirculation-related disease prevention and control, high-end medical device research and development, and optimization of chronic disease management systems [1] - The center aims to significantly enhance the demonstration and leading effect of "Science and Technology Innovation China" in Suzhou [1] - Since its founding in 1993, the Chinese Microcirculation Society has been deeply involved in academic research, clinical transformation, and industry-education integration in the microcirculation field [2] Group 2 - The society has established strong academic foundations and rich expert resources in areas such as cardiovascular and cerebrovascular diseases, diabetic complications, tumor microenvironments, and tissue engineering [2] - In the current year, the society has organized over 60 experts to engage with 39 local biomedicine companies and 24 research institutions and hospitals in Suzhou, resulting in 15 cooperation intentions [2] - The society has also provided professional technical guidance to 10 local enterprises [2]

Core Insights - A new eye implant system has been developed that can help 80% of patients with age-related macular degeneration partially regain their vision [1][2] - Age-related macular degeneration is the leading cause of blindness globally, particularly affecting individuals over 60 years old [1] - The system, named Prima, consists of a retinal implant and augmented reality glasses, designed to replace lost photoreceptor cells due to the disease [2] Group 1 - The Prima system includes a 2mm x 2mm retinal implant that is 30 micrometers thick, which is surgically placed beneath the retina [2] - The augmented reality glasses are equipped with a mini camera that captures images and processes them through a computer to enhance contrast and brightness before projecting them as infrared light onto the retinal implant [2] - Clinical trials involved 38 patients with severe vision impairment, with 32 completing the study [2] Group 2 - After one year of using the Prima system, 81% of participants could read at least 10 more letters on a vision chart, and 78% could read at least 15 more letters [2] - The best-performing participant was able to read 59 additional letters, and 84.4% of participants reported being able to read letters, numbers, and words [2] - A total of 26 serious adverse events were observed among 19 participants, all of which were anticipated risks, including high intraocular pressure and subretinal hemorrhage, with most resolving on their own or through medical intervention [2]

Core Viewpoint - Zhejiang University School of Medicine's Shao Yifu Hospital has developed the world's first biodegradable bone glue, "Bone 02," inspired by the adhesion mechanism of oysters, which can bond bone fragments effectively in a blood environment [1][2]. Summary by Sections Product Development - "Bone 02" is designed to bond bone fragments in various fracture types, potentially reducing or replacing traditional metal fixation methods [1]. - The development team conducted rigorous clinical trials over eight months, involving over 150 patients, demonstrating good safety and efficacy [1][2]. Technical Aspects - The material consists of a liquid phase and a solid phase, both of which are biocompatible and consist of components already present in the human body [3]. - The adhesive mechanism allows for rapid solidification within three minutes, creating a strong bond with bone tissue [4]. Performance Metrics - Key performance indicators include adhesion strength, operational time, and biocompatibility, which were optimized through extensive testing and iterations [5]. - The final formulation allows for a 3 to 5-minute operational window before solidification begins, ensuring sufficient time for precise application during surgery [5]. Clinical Advantages - Compared to traditional metal fixation, "Bone 02" reduces surgical time, minimizes tissue trauma, and accelerates recovery [11]. - The product's biodegradable nature eliminates the need for secondary surgeries to remove metal implants, thus reducing overall healthcare costs [15]. Future Applications - The technology is expected to shift orthopedic surgery paradigms from mechanical fixation to biological healing, with potential applications in various fields, including dental implants and spinal surgery [19][20]. - "Bone 02" is anticipated to be approved for widespread clinical use within the next two to three years [20]. Emergency Use - The product's simplicity and rapid application make it suitable for emergency situations, such as battlefield or disaster scenarios, where quick stabilization of injuries is critical [18].

Core Viewpoint - The development of a new bone adhesive material named "Bone 02" by Zhejiang University Shao Yifu Hospital shows promising results in treating comminuted fractures, demonstrating good safety and efficacy in clinical trials involving over 150 patients [1][2]. Group 1: Product Development - The "Bone 02" material was inspired by the biological adhesion mechanism of oysters and underwent over 50 formula iterations and hundreds of tests to overcome key challenges such as biotoxicity and adhesion strength in blood environments [2]. - The maximum adhesive pull force of "Bone 02" can reach over 400 pounds, indicating its potential to replace traditional metal fixation devices while reducing the risk of foreign body reactions and infections [2]. Group 2: Clinical Application - The new adhesive material is applicable for fixing bone fragments of various sizes and can significantly enhance surgical efficiency and reduce trauma during operations, contributing to minimally invasive orthopedic surgeries [2]. - "Bone 02" is expected to be useful in emergency situations such as military operations and disaster rescue, where rapid and effective fracture treatment is critical [2].

Core Viewpoint - The establishment of the Zero Magnetic Interventional Medicine Laboratory at Fudan University Affiliated Pudong Hospital represents a significant advancement in the integration of zero magnetic medicine and advanced interventional medicine, aiming for early non-invasive diagnosis of diseases with high precision and resolution [1][2]. Group 1: Laboratory Establishment and Collaboration - The Zero Magnetic Interventional Medicine Laboratory is led by Fudan University Affiliated Pudong Hospital and integrates resources from several prestigious hospitals and universities, forming a high-level academic team and a complete innovation transformation chain from theoretical research to technology development and industrial application [1]. - A four-party strategic cooperation agreement was signed among Fudan University Affiliated Pudong Hospital, Beihang University Large Scientific Device Research Institute, Hangzhou Weak Magnetic Field National Major Science and Technology Infrastructure Research Institute, and related enterprises [1]. Group 2: Technological Advancements and Research Focus - Academician Fang Jiancheng emphasized that weak magnetic fields are a new scientific discovery that complements structural imaging technologies, aiming to build a comprehensive health detection system for the human body [2]. - The laboratory will focus on the research and development of intelligent zero magnetic interventional materials and devices, establish clinical technical guidelines, and cultivate high-level talent, ultimately creating a national-level center for the promotion and application of zero magnetic interventional medicine technology [2]. Group 3: Future Directions and Benefits - The laboratory aims to enhance the deep research and application promotion of zero magnetic technology in interventional medicine, strengthening interdisciplinary collaboration and results transformation [3]. - The collaboration is expected to provide better early screening and treatment options for cardiac and brain diseases, benefiting a larger population [2].

Core Viewpoint - Huaborn Neutron Technology Co., Ltd. has completed a multi-hundred million RMB Pre-A round financing, indicating strong market confidence in Boron Neutron Capture Therapy (BNCT) as a promising treatment method [2][11]. Company Overview - Established in 2023 and headquartered in Hangzhou, Zhejiang, Huaborn Neutron is a national high-tech enterprise focused on the research, production, and application of accelerator-driven BNCT technology [3]. - The company was founded by Wang Sheng, a renowned neutron scientist, and has assembled a team of experts across various disciplines including nuclear physics, software, control, mechanics, pharmacy, clinical medicine, and materials science [3]. Main Products and Technologies - Huaborn Neutron has developed the HyBorSys® BNCT full-process solution, which includes an accelerator neutron source system, boron drugs, and a treatment planning system (TPS), achieving a complete closed-loop for BNCT technology [4]. - The BNCT equipment utilizes a high-current proton RFQ accelerator and long-life solid lithium target technology, ensuring high power stability and a target lifespan that is globally leading (>1500 mA·h) [6]. - The company has established a research and development system for boron drug synthesis, significantly improving product quality and reducing production costs [7]. - The domestically developed TPS can model based on multi-modal imaging data from patients, simulating dose distribution using Monte Carlo particle transport programs for precise prediction and individualized treatment planning [9]. Current Status and Future Prospects - The HyBorSys® demonstration device has completed medical device registration inspection, and the boron drug is about to enter the IND application stage [10]. - BNCT is recognized as a significant breakthrough in the field of radiotherapy, gradually moving towards clinical application, with Huaborn Neutron achieving independent breakthroughs in devices, drugs, and software within two years [11]. - The recent financing round, attracting several hundred million RMB, reflects the capital market's high recognition of BNCT as a cutting-edge therapy [11].

Employment Market Overview - The employment rate for individuals aged 16-64 in the UK rose to 75.1% from February to April 2025, indicating a positive aspect of the job market [1] - However, the number of salaried employees decreased by 55,000 (0.2%) in March-April 2025 and by 115,000 (0.4%) from April 2024 to April 2025, suggesting a cautious hiring strategy among UK businesses [1][3] Public vs. Private Sector Employment - Public sector employment remained stable at 6.15 million in March 2025, with a year-on-year growth of 0.6%, while private sector employment growth faced different challenges [3] - This disparity provides insights for investors, indicating that stable public sector-related industries may offer defensive investment opportunities, while emerging sectors in the private sector also hold potential [3] Unemployment and Economic Inactivity - The unemployment rate for individuals aged 16 and above reached 4.6% from February to April 2025, showing an increase both year-on-year and quarter-on-quarter, which raises concerns about economic growth [3] - The economic inactivity rate for those aged 16-64 decreased to 21.3%, but a significant portion is attributed to long-term illness and students, highlighting structural issues in the labor market [3] Wage Growth and Job Vacancies - Average wage growth for employees was notable, with regular wages increasing by 5.2% and total wages by 5.3% from February to April 2025, leading to improved consumer purchasing power [4] - Job vacancies fell to 736,000 from March to May 2025, marking a continuous decline over 35 quarters, indicating weakened labor demand and cautious investment in labor-intensive sectors [4] Consumer Sector Opportunities - With rising wages, the consumer sector is expected to experience growth, particularly in mid-to-high-end consumption areas such as premium retail, quality dining, and personalized travel services [5] - UK high-end fashion brands may benefit from increased disposable income, leading to higher sales, while specialty tourism projects and luxury hotels are also likely to gain from the consumption upgrade trend [5] Healthcare Sector Investment Potential - The high proportion of long-term illness in the economically inactive population underscores pressure on the UK healthcare system, presenting investment opportunities in medical device development and biopharmaceuticals focused on chronic disease treatment [6] Education and Training Sector Growth - The shortage of skilled labor in the UK is driving demand for education and training, particularly in vocational skills training and online education platforms, which are poised for significant growth [7] Human Resources Services Demand - Despite an overall decline in job vacancies, there remains a strong demand for high-end and specialized talent recruitment, suggesting that human resources service firms focusing on high-end talent acquisition may thrive [8]

Core Insights - The article provides an overview of the latest trends in investment and financing activities in the domestic market, highlighting key sectors and significant funding events [3]. Group 1: Investment Overview - A total of 66 financing events were disclosed in the domestic primary market this week, a decrease of 36 events compared to the previous week [5]. - Among the disclosed financing events, 21 had reported amounts, with a total financing scale of 4.17 billion RMB, resulting in an average financing amount of 199 million RMB [5]. Group 2: Sector Distribution - The most active sectors in terms of financing events were intelligent manufacturing, artificial intelligence, and healthcare, with 20, 18, and 7 events respectively [7]. - In terms of disclosed financing amounts, artificial intelligence led with a total financing scale of approximately 1.41 billion RMB, highlighted by TARS, an AI-driven embodied intelligence technology company, which completed a $120 million angel round [7][8]. - The healthcare sector followed with a disclosed financing total of 1.32 billion RMB, with Ruiqiao Dingke, a medical device developer in chronic disease management, completing a 1 billion RMB Series A financing [9]. Group 3: Regional Distribution - The disclosed investment events were primarily concentrated in Jiangsu, Guangdong, and Shanghai, with 17, 14, and 11 events respectively [13]. - Jiangsu reported a total financing of 300 million RMB across 3 disclosed events, while Shanghai had 22.92 billion RMB from 7 disclosed events [16]. Group 4: Stage Distribution - The majority of the disclosed investment events were early-stage, with 51 events, followed by 14 growth-stage events and 1 late-stage event [17]. Group 5: Major Financing Events - Significant financing events included Ruiqiao Dingke's Series A round exceeding 1 billion RMB and TARS's angel round of $120 million [22][23]. Group 6: M&A Activity - There were 7 disclosed completed M&A events this week, a decrease of 7 compared to the previous week, with notable transactions including the acquisition of Longsheng New Energy by Saisir for 8.164 billion RMB [42][44].